Literature DB >> 22677416

Preparation of medicines for children - a hierarchy of classification.

Terry B Ernest1, Jo Craig, Anthony Nunn, Smita Salunke, Catherine Tuleu, Joerg Breitkreutz, Rainer Alex, John Hempenstall.   

Abstract

There is some confusion about the types of paediatric pharmaceutical preparation (in a regulatory and pharmaceutical development context) that are acceptable for approval by medicines regulators. Some of the confusion relates to terminology which may mean different things to different stakeholders. It may not always be possible to provide authorised, commercially manufactured, age appropriate, ready-to-administer preparations. In terms of assurance of quality and bioavailability there is a continuum from this ideal through intermediate products through authorised compounding and manipulation of commercial dosage forms to ad hoc compounding using only the skills and experience of the individual pharmacist. Additionally, it is widely known that caregivers may manipulate medicines at home, for example by segmenting tablets and by addition to foods or liquids. The first intent of the manufacturer should be to provide for children an age appropriate, ready-to-administer preparation which is commercially manufactured and approved by the competent authorities. However, there will still be a place for providing other age appropriate preparations such as approved products that are 'intermediates' requiring reconstitution before use, or instructions for compounding or manipulation of a dosage form. If compounding or manipulation is likely to be required it is preferable that data are generated by Industry, approved by the competent authorities and provided in the Summary of Product Characteristics (SmPC). It is acknowledged however, that ad hoc compounding or manipulation may also take place in certain circumstances such as logistical difficulties or to satisfy the needs of the child who does not find the authorised product to be 'age appropriate'. This paper explores compounding and manipulation of medicines in relation to approval by medicines regulators and non-approved preparation to fulfil the needs of the individual patient. Definitions are proposed to provide a hierarchical classification based on assurances of quality and bioavailability.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677416     DOI: 10.1016/j.ijpharm.2012.05.070

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

1.  Unlicensed and off-label use of medicines in children admitted to the intensive care units of a hospital in Malaysia.

Authors:  Jian Lynn Lee; Adyani Md Redzuan; Noraida Mohamed Shah
Journal:  Int J Clin Pharm       Date:  2013-12

Review 2.  Educational paper: formulation-related issues in pediatric clinical pharmacology.

Authors:  Catherine Tuleu; Joerg Breitkreutz
Journal:  Eur J Pediatr       Date:  2012-10-31       Impact factor: 3.183

3.  Pediatric clinical pharmacology: an introduction to a series of educational papers.

Authors:  Karel Allegaert
Journal:  Eur J Pediatr       Date:  2013-01-05       Impact factor: 3.183

4.  Development and evaluation of an assessment of the age-appropriateness/inappropriateness of formulations used in children.

Authors:  Jennifer C Duncan; Louise E Bracken; Anthony J Nunn; Matthew Peak; Mark A Turner
Journal:  Int J Clin Pharm       Date:  2022-10-08

5.  Solid oral forms availability in children: a cost saving investigation.

Authors:  Audrey Lajoinie; Emilie Henin; Behrouz Kassai; David Terry
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

6.  Microbiological quality control of non-sterile compounded medicines prepared in a Portuguese hospital centre.

Authors:  R Palmeira-de-Oliveira; C Luís; C Gaspar; E Bogas; M Morgado; M Guardado; M Castelo Branco; M O Fonseca; A Palmeira-de-Oliveira
Journal:  Eur J Hosp Pharm       Date:  2016-01-19

7.  Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.

Authors:  J Martir; T Flanagan; J Mann; Nikoletta Fotaki
Journal:  AAPS PharmSciTech       Date:  2020-10-15       Impact factor: 3.246

8.  Implementation of a New Electronic Liquid Dispensing System for Individualized Compounding of Hard Capsules.

Authors:  Bakul Sarker; Mariele Fligge; Tanja Knaab; Jörg Breitkreutz
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

Review 9.  Improving antibiotic prescribing for children in the resource-poor setting.

Authors:  Kirsty Le Doare; Charlotte I S Barker; Adam Irwin; Mike Sharland
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

10.  Academic pediatric clinical research: factors associated with study implementation duration.

Authors:  Delphine Meier-Girard; Annick Tibi; Hendy Abdoul; Sonia Prot-Labarthe; Françoise Brion; Olivier Bourdon; Corinne Alberti
Journal:  BMC Med Res Methodol       Date:  2016-03-29       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.